Peripartum Cardiomyopathy: Do Exosomes Play a Role?
Peripartum Cardiomyopathy: Do Exosomes Play a Role?
复制标题
围产期心肌病：外泌体发挥作用吗？
DOI：
10.1007/978-981-10-4397-0_9
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Zhou Lei
中科院分区：
文献类型：
--
作者：
Gu Huanyu;Dai Qiying;Liu Zhuyuan;Wang Hongbao;Yao Jianhua;Zhou Lei
围产期心肌病(PPCM)是指在怀孕最后一个月或分娩后5个月内发生的不可逆转的心肌细胞损伤。它的特点是收缩性心力衰竭。这种危及生命的情况相对较少，但发病率一直在上升。由于其高死亡率，医生对该病的高度怀疑是至关重要的。已经进行了研究，以探索PPCM的特定实验室测试和治疗。已经探索了抗病毒、抗炎和免疫抑制方案等治疗方法。像Exosome这样的新疗法也被探索出来，并显示出有希望的效果。
Peripartum cardiomyopathy (PPCM) refers to irreversible cardiomyocyte damage that occurs during the last month of pregnancy, or within 5 months after giving birth. It is characterized by systolic heart failure. This life-threatening condition is relatively uncommon, but the incidence has been climbing up. Because of its high mortality, it is crucial for physicians to have high suspicious for the disease. Studies have been done to search into specific lab test and treatment for PPCM. Therapies like anti-viral, anti-inflammatory and immunosuppression regimen have been explored. New regimen like exosomes has also been explored and revealed promising effects.